Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

tri-specific NK cell engager CC-92328

A tri-specific natural killer (NK) cell engager, with potential immunomodulating and antineoplastic activities. Upon administration, the tri-specific NK cell engager CC-92328 binds to as of yet unelucidated proteins expressed on both cancer cells and NK cells, thereby bringing cancer cells and NK cells together. This stimulates the NKs and allows for NK-mediated cancer cell killing. In addition, the NKs activate T and B cells, and enhance a cytotoxic T-lymphocyte (CTL) immune response against cancer cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	tri-specific NK cell engager therapeutic agent CC-92328 TriNKET CC-92328
Code name:	CC 92328 CC-92328 CC92328

tri-specific NK cell engager CC-92328

Search NCI's Drug Dictionary